Send us a text

Thursday, June 8 was International #NASHDay 2023 and the podcast hosted a special session featuring patient advocates Gina Villiotti Madison (NASH kNOWledge), Marko Korenjak (European Liver Patients'​ Association) and Michael Betel (Fatty Liver Alliance). With co-hosts Louise Campbell and Roger Green, the group shares both a positive and sobering discussion around the Fatty Liver public health epidemic and its impact on younger generations now and into the imminent future. Each guest discusses what their respective organizations are doing in support of International #NASHDay and the conversations that follow invoke a sense of urgency to take action as a community. This is a particularly important and moving episode that captures a range of topics pertinent to the patient perspective and, more broadly, stepping up to NASH.

If you have questions or interest around the International #NASHDay 2023, we kindly ask that you submit reviews wherever you download our discussions. Alternatively, you can write to us directly at [email protected]. We welcome all stories around how you and your community stepped up to NASH this year and look forward to broadening the discourse.

Stay Safe and Surf On!

This episode was generously sponsored by Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist designed to target key underlying causes of NASH in the liver. For more information, visit www.madrigalpharma.com.